Jefferies initiated coverage on CinCor Pharma with a new price target
$CINC
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of CinCor Pharma with a rating of Buy and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2022 | $22.00 | Overweight | Barclays |
| 11/29/2022 | Outperform → Perform | Oppenheimer | |
| 11/29/2022 | $60.00 → $22.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/28/2022 | $67.00 | Buy | Goldman |
| 8/22/2022 | $73.00 | Overweight | Piper Sandler |
| 2/1/2022 | Outperform | Evercore ISI | |
| 2/1/2022 | $30.00 | Outperform | Oppenheimer |
| 2/1/2022 | $27.00 | Overweight | Morgan Stanley |